A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia
Male
150
treatment retention
opioid substitution treatment
anzsrc-for: 4206 Public Health
methadone
Substance Misuse
Longitudinal Studies
Analgesics
anzsrc-for: 42 Health Sciences
treatment
3 Good Health and Well Being
Middle Aged
buprenorphine
3. Good health
Buprenorphine
Analgesics, Opioid
52 Psychology
4206 Public Health
Female
Crime
New South Wales
Adult
Patient Dropouts
610
Opioid
Medication Adherence
anzsrc-for: 52 Psychology
Young Adult
Clinical Research
XXXXXX - Unknown
Opiate Substitution Treatment
Humans
anzsrc-for: 17 Psychology and Cognitive Sciences
Proportional Hazards Models
Retrospective Studies
Assessment of Medication Adherence
580
Australia
42 Health Sciences
opioids
Opioid-Related Disorders
Brain Disorders
anzsrc-for: 5203 Clinical and Health Psychology
anzsrc-for: 11 Medical and Health Sciences
opioid dependence
5203 Clinical and Health Psychology
Multivariate Analysis
Drug Abuse (NIDA only)
dependency
Methadone
DOI:
10.1111/add.12834
Publication Date:
2014-12-16T20:38:55Z
AUTHORS (10)
ABSTRACT
AbstractBackground and AimsTo examine characteristics of first‐time methadone and buprenorphine clients and factors associated with risk of leaving first treatment in New South Wales (NSW), Australia.DesignRetrospective linkage study of opioid substitution therapy (OST) treatment, court, custody and mortality data.SettingNSW, Australia.ParticipantsFirst‐time OST entrants (August 2001–December 2010).MeasurementsCharacteristics of clients were examined. Time‐dependent Cox models examined factors associated with the risk of leaving first treatment, with demographic, criminographic and treatment variables jointly considered. Interactions between medication and other variables upon risk of leaving treatment were examined.FindingsThere were 15 600 treatment entrants: 7183 (46%) commenced buprenorphine, 8417 (54%) commenced methadone; the proportion entering buprenorphine increased over time. Those starting buprenorphine switched medications more frequently and had more subsequent treatment episodes. Buprenorphine retention was also poorer. On average, 44% spent 3+ months in treatment compared with 70% of those commencing methadone; however, buprenorphine retention for first‐time entrants improved over time, whereas methadone retention did not. Multivariable Cox models indicated that in addition to sex, age, treatment setting and criminographic variables, the risk of leaving a first treatment episode was greater on any given day for those receiving buprenorphine, and was dependent on the year treatment was initiated. There was no interaction between any demographic variables and medication received, suggesting no clear evidence of any particular groups for whom each medication might be better suited in terms of improving retention.ConclusionsAlthough retention rates for buprenorphine treatment have improved in New South Wales, Australia, individuals starting methadone treatment still show higher retention rates.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (11)
CITATIONS (58)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....